Implant-associated anaplastic large cell lymphoma (literature review)
Колеснік О.П. 1, Кечеджиєв В.В.1, Левик О.М.1, Кузьменко В.О.1, Kabakov A.O.2
Summary. In recent years, there is increasing evidence that breast implants, in rare cases, may be associated with the development of anaplastic large-cell lymphoma (ALCL). According to the literature, the incidence rate of primary anaplastic large cell lymphoma (BIA-ALCL) is estimated at 1 in 30,000 women with textured breast implants. BIA-ALCL occurs in the implant bed after breast reconstruction in women with breast cancer or augmentation. Histologically confirmed BIA-ALCL requires individual treatment by a multidisciplinary team of a clinical oncologist, oncological surgeon, plastic surgeon and hematologist. Treatment BIA-ALCL gives a much better prognosis than at systemic ALCL. Moreover, BIA-ALCL, limited by capsule, has favorable forecast after surgical capsulectomy, even without adjuvant chemotherapy or radiotherapy. However, some patients develop an infiltrative disease with a potentially life-threatening clinical course.
Leave a comment